Iricryn

Bimatoprost, the active ingredient in Iricryn, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for open‑angle glaucoma and ocular hypertension.

GNH USA supplies Iricryn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iricryn (bimatoprost) is a prostaglandin analog used to manage ocular conditions characterized by elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers eye pressure in patients at risk of developing glaucoma.

Bimatoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Conjunctival hyperemia (eye redness). - Increased eyelash length and density. - Eye irritation or foreign‑body sensation. - Blurred vision. - Darkening of the iris. - Dry eye sensation.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema). - Uveitis or intra‑ocular inflammation. - Macular edema leading to vision changes. - Sudden loss of vision. - Ocular infection. - Persistent corneal edema.

Before prescribing Iricryn, clinicians should consider several safety measures.

Monitor intra‑ocular pressure regularly: ensure therapeutic effect and detect hypotony. Assess for active ocular infection or inflammation: avoid use until resolved. Avoid use in patients with a history of uveitis: risk of exacerbation. Caution with contact lens wearers: lenses may retain the drug and increase irritation. Pregnancy and breastfeeding safety unknown: weigh potential risks and benefits. Store at room temperature: keep in the original container, protect from light and moisture.

Bimatoprost can interact with other ocular or systemic agents, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops: additive ocular side effects. - Use with ocular anesthetics containing preservatives: increased risk of corneal toxicity.

Moderate Interactions (Monitor Closely): - Systemic beta‑blockers: may mask IOP changes. - Carbonic anhydrase inhibitors: potential for excessive IOP reduction. - Anticholinergic eye drops: may affect tear film stability.